Skip to main content

Idarucizumab in Dabigatran-Treated Patients Requiring Emergency Surgery or Intervention: Updated/Final Results From the RE-VERSE AD Study

Publication ,  Conference
Levy, J; Sellke, F; Reilly, PA; VanRyn, J; Kreuzer, J; Weitz, J; Pollack, C
Published in: CIRCULATION
2017

Duke Scholars

Published In

CIRCULATION

EISSN

1524-4539

ISSN

0009-7322

Publication Date

2017

Volume

136

Related Subject Headings

  • Cardiovascular System & Hematology
  • 4207 Sports science and exercise
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology
  • 1117 Public Health and Health Services
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Levy, J., Sellke, F., Reilly, P. A., VanRyn, J., Kreuzer, J., Weitz, J., & Pollack, C. (2017). Idarucizumab in Dabigatran-Treated Patients Requiring Emergency Surgery or Intervention: Updated/Final Results From the RE-VERSE AD Study. In CIRCULATION (Vol. 136).
Levy, Jerrold, Frank Sellke, Paul A. Reilly, Joanne VanRyn, Jorg Kreuzer, Jeffrey Weitz, and Charles Pollack. “Idarucizumab in Dabigatran-Treated Patients Requiring Emergency Surgery or Intervention: Updated/Final Results From the RE-VERSE AD Study.” In CIRCULATION, Vol. 136, 2017.

Published In

CIRCULATION

EISSN

1524-4539

ISSN

0009-7322

Publication Date

2017

Volume

136

Related Subject Headings

  • Cardiovascular System & Hematology
  • 4207 Sports science and exercise
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology
  • 1117 Public Health and Health Services
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology